These could help to identify new markers beside mTOR activity characterisation—such as FASN, CPT1a, ACSS2—or find good mitochondrial function markers (e.g. TOM20, NRF1), and to assign the metabolic expression profile of tumours before starting treatments in patients. This evidence concerns the gene CPT1A and neoplasm.